Results 31 to 40 of about 2,705 (182)

Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children [PDF]

Human Vaccines & Immunotherapeutics
Vaccine safety and immunogenicity data in human immunodeficiency virus (HIV)-exposed uninfected (HEU) children are important for decision-making in HIV and typhoid co-endemic countries.
Nginache Nampota-Nkomba, Osward M. Nyirenda, Victoria Mapemba, Rhoda Masonga, Priyanka D. Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, John M. Ndaferankhande, Bright Lipenga, Pratiksha Patel, Happy Banda, Jennifer Oshinsky, Marcela F. Pasetti, Robert S. Heyderman, Leslie P. Jamka, Divya Hosangadi, Shrimati Datta, Melita A. Gordon, Kathleen M. Neuzil, Matthew B. Laurens   +20 more
doaj   +2 more sources

Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

International Journal of Infectious Diseases, 2021
Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority.
Sodiomon B. Sirima, Alphonse Ouedraogo, Nouhoun Barry, Mohamadou Siribie, Alfred Tiono, Issa Nébié, Amadou Konaté, Gloria Damoaliga Berges, Amidou Diarra, Moussa Ouedraogo, Edith C. Bougouma, Issiaka Soulama, Alimatou Hema, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Kathleen Tracy, Leslie P. Jamka, Jennifer J. Oshinsky, Marcela F. Pasetti, Kathleen M. Neuzil, Matthew B. Laurens   +21 more
doaj   +3 more sources

Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan. [PDF]

Vaccine, 2023
Background: This study aimed to evaluate the parental acceptance of Typhoid Conjugate Vaccine (TCV) and to determine the predictors of TCV vaccination status among children in an outbreak setting of extensively drug resistant (XDR) typhoid fever in ...
Batool R, Yousafzai MT, Qureshi S, Muhammad S, Qazi I, Sadaf T, Ashorn P, Qamar FN.   +7 more
europepmc   +2 more sources

Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. [PDF]

Vaccine, 2023
Models are useful to inform policy decisions on typhoid conjugate vaccine (TCV) deployment in endemic settings. However, methodological choices can influence model-predicted outcomes.
Burrows H, Antillón M, Gauld JS, Kim JH, Mogasale V, Ryckman T, Andrews JR, Lo NC, Pitzer VE.   +8 more
europepmc   +2 more sources

Introduction of Typhoid Conjugate Vaccines in Africa and Asia [PDF]

Clinical Infectious Diseases, 2019
Typhoid fever continues to be a major public health concern, particularly in many low- and middle-income countries. The current threats of increasing antimicrobial resistance, urbanization, and climate change elevate the urgency for better prevention and control efforts for typhoid fever.
Neuzil, K, Pollard, A, Marfin, A
openaire   +2 more sources

Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data. [PDF]

Lancet Glob Health, 2023
BackgroundTyphoid conjugate vaccines are being introduced in low-income and middle-income countries to prevent typhoid illness in children. Vaccine effectiveness studies assess vaccine performance after introduction.
Liang Y, Driscoll AJ, Patel PD, Datta S, Voysey M, French N, Jamka LP, Henrion MYR, Ndeketa L, Laurens MB, Heyderman RS, Gordon MA, Neuzil KM.   +12 more
europepmc   +2 more sources

A Race against Time: Reduced Azithromycin Susceptibility in Salmonella enterica Serovar Typhi in Pakistan

mSphere, 2020
Antimicrobial resistance is an ongoing issue in the treatment of typhoid fever. Resistance to first-line antimicrobials and extensively drug resistant (XDR) Salmonella Typhi isolates in Pakistan have left azithromycin as the only remaining effective oral
Junaid Iqbal, Irum F. Dehraj, Megan E. Carey, Zoe A. Dyson, Denise Garrett, Jessica C. Seidman, Furqan Kabir, Senjuti Saha, Stephen Baker, Farah N. Qamar   +9 more
doaj   +3 more sources

One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine

International Journal of Infectious Diseases, 2020
Introduction: World Health Organization estimates the annual global incidence of typhoid fever at 11-21 million cases and approximately 128 000 to 161 000 deaths.
Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, Hartono Gunardi, Rini Sekartini, Hindra Irawan Satari, Sri Rezeki Hadinegoro, Angga Wirahmadi, Mita Puspita, Rini Mulia Sari, Jae Seung Yang, Arijit Sil, Sushant Sahastrabuddhe, Novilia Sjafri Bachtiar   +12 more
doaj   +1 more source

Strategies for typhoid conjugate vaccines in endemic nations – Authors' reply [PDF]

The Lancet Infectious Diseases, 2021
Vaccines against typhoid fever have been shown to be safe and effective in field trials. The mechanism through which the vaccines protect remains elusive. Recent data have implicated antibody glycosylation, and specifically afucosylated antibodies, as an
Virginia E, Pitzer, Andrew J, Pollard, Joke, Bilcke   +2 more
openaire   +4 more sources

Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal

, 2022
Globally, an estimated 11 to 21 million cases of febrile illness and 117,000 to 161,000 deaths are attributed to typhoid fever each year. Typhoid fever is prevalent mainly in low-resource settings with poor water, and inadequate sanitation and hygiene ...
Shakya, Mila
core   +1 more source